KaRa MINDS is a COVID-19 safe business, and all care is taken to ensure the safety of our participants and staff. Please advise us if you have any concerns about your health prior to attending any appointment.
At KaRa MINDS, we collaborate with international, national and local partners to prevent and treat neurological conditions such as Alzheimer's disease through research.
Studies open now for recruitment
Cassava Study - phase 2 (12m)
A Randomized, Placebo-Controlled, investigating Simufilam for the treatment of mild to moderate Alzheimer’s disease.
XPRO-AD-02 - phase 2 (6m)
A Randomized, Placebo-Controlled study, investigating XPro1595 for the treatment of mild Alzheimer’s disease targeting inflammation.
INVOKE - Phase 2 (24m)
A Randomized, Placebo-Controlled, investigating AL002 for the treatment of mild to moderate Alzheimer’s disease.
EVOKE Plus - Phase 2 - (24m)
A Randomized, Placebo-Controlled, investigating Semaglutide for the treatment of MCI – early Alzheimer’s disease.
Envision - Phase 4 - pending (24m)
A Randomized, Placebo-Controlled, investigating Aducanumab for the treatment of MCI – early Alzheimer’s disease.
MK-1942 – Phase 2a/b – pending (6m)
A Randomized, Placebo-Controlled, investigating MK-1942 as adjunctive treatment in participants with Mild to Moderate Alzheimer’s disease.
LAKD Trailrunner – Phase 3 (24-36 m)
A Randomized, Placebo-Controlled, investigating Remternetug (LY3372993) for the treatment of Early symptomatic Alzheimer’s Disease.
For further details on any study, please call KaRa MINDS or use the Contact Us form at the bottom of the page and our friendly team will be in touch.
Studies running - recruitment closed
A Randomized, Phase 2, Placebo-Controlled, study to investigate the efficacy of LY3372689 in MCI to early Alzheimer’s disease.
ANAVEX AD Study Open label
A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled investigating ANAVEX2-73 for the treatment of Early Alzheimer’s disease.
Assessment, tolerability and efficacy of Donanemab in early symptomatic Alzheimer’s Disease, 76-week duration. A Phase 3 Study, 1 ½ year study.
Clarity Study (open Label)
A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease.
Phase 3b open-label, multicentre, safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies.
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients with Mild to Moderate Alzheimer’s Disease with Elevated high sensitivity C-reactive protein in Blood.
A Phase 2, Double-Blind, Randomized, Placebo-Controlled 52-week clinical proof of concept study for the treatment of Deferiprone to Delay Dementia.
Longitudinal investigational study examining blood, brain and lifestyle risk factors in an older at risk of AD population.
ATHIRA ACT Study
A Randomized, Phase 2, Placebo-Controlled, Translational Study of ATH-107 in Subjects with Mild to Moderate Alzheimer's Disease.
ANAVEX Parkinson's related dementia
A Phase 2, Double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of ANAVEX2-73 for cognitive impairment in patients with Parkinson’s Disease with dementia.
Mission AD Study
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease.
A Phase II, Double -Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of XanamemTM in Subjects with Mild Dementia due to Alzheimer’s disease.
Biomarker qualification for risk of mild cognitive impairment due to Alzheimer’s disease and safety and efficacy evaluation of Pioglitazone in delaying its onset (TOMORROW).
A Phase 2b/3 randomised, double-blind, placebo-controlled, parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in subjects who are Asymptomatic and at risk for developing Alzheimer's disease.
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with early Alzheimer’s disease.
A multinational, multi-center, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer’s disease.
Investigation of curcumin for the prevention of Alzheimer’s disease in cognitively healthy individuals, examining the blood, brain and retina.
A 56-week, Double-Blind, Randomised Study to Evaluate the Efficacy of Testosterone, With and Without DHA Supplementation on Cerebral Amyloid Load in Known Brain Amyloid-PET Positive Men with Subjective Memory Complaints.
An open label, 12-week study to investigate the efficacy and safety of XPRO 1595 in Subjects with early-mod Alzheimer's disease.